JP2021525752A5 - - Google Patents

Info

Publication number
JP2021525752A5
JP2021525752A5 JP2020566834A JP2020566834A JP2021525752A5 JP 2021525752 A5 JP2021525752 A5 JP 2021525752A5 JP 2020566834 A JP2020566834 A JP 2020566834A JP 2020566834 A JP2020566834 A JP 2020566834A JP 2021525752 A5 JP2021525752 A5 JP 2021525752A5
Authority
JP
Japan
Prior art keywords
present
activation
novel heterocyclic
stat3 protein
suppresses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566834A
Other languages
English (en)
Japanese (ja)
Other versions
JP7558066B2 (ja
JP2021525752A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2019/006554 external-priority patent/WO2019231271A1/en
Publication of JP2021525752A publication Critical patent/JP2021525752A/ja
Publication of JP2021525752A5 publication Critical patent/JP2021525752A5/ja
Application granted granted Critical
Publication of JP7558066B2 publication Critical patent/JP7558066B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566834A 2018-05-31 2019-05-31 複素環誘導体及びその使用 Active JP7558066B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0062450 2018-05-31
KR20180062450 2018-05-31
PCT/KR2019/006554 WO2019231271A1 (en) 2018-05-31 2019-05-31 Heterocyclic derivatives and use thereof

Publications (3)

Publication Number Publication Date
JP2021525752A JP2021525752A (ja) 2021-09-27
JP2021525752A5 true JP2021525752A5 (https=) 2022-03-31
JP7558066B2 JP7558066B2 (ja) 2024-09-30

Family

ID=68698337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566834A Active JP7558066B2 (ja) 2018-05-31 2019-05-31 複素環誘導体及びその使用

Country Status (8)

Country Link
US (1) US12404249B2 (https=)
EP (1) EP3802495B1 (https=)
JP (1) JP7558066B2 (https=)
KR (1) KR102229471B1 (https=)
CN (1) CN112204010B (https=)
ES (1) ES3041067T3 (https=)
TW (1) TWI853814B (https=)
WO (1) WO2019231271A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110105237B (zh) * 2019-06-06 2021-12-24 东北师范大学 一种β-偕二氟叠氮化合物及其制备和应用
WO2022187411A1 (en) * 2021-03-02 2022-09-09 Kumquat Biosciences Inc. Heterocycles and uses thereof
CN113845476B (zh) * 2021-11-08 2024-04-30 中国药科大学 一种喹诺酮衍生物及其制备方法和用途
CN114315802B (zh) * 2021-12-14 2023-06-16 西安医学院 一种喹唑啉含氮杂环衍生物及制备方法和用途
AU2023255692A1 (en) 2022-04-20 2024-10-03 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
EP4296674A1 (en) 2022-06-20 2023-12-27 Université Toulouse III - Paul Sabatier Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007566A (ko) 1994-08-19 1996-03-22 김정규 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
WO2001081345A1 (en) * 2000-04-20 2001-11-01 Mitsubishi Pharma Corporation Aromatic amide compounds
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
EP1689753A4 (en) 2003-12-04 2010-07-07 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20060074105A1 (en) * 2004-09-20 2006-04-06 Serenex, Inc. Substituted quinoline and quinazoline inhibitors of quinone reductase 2
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
WO2007083978A1 (en) 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
WO2008086462A2 (en) * 2007-01-11 2008-07-17 Wyeth AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
WO2009108670A1 (en) 2008-02-28 2009-09-03 Merck Serono S.A. Protein kinase inhibitors and use thereof
US8466290B2 (en) 2008-07-10 2013-06-18 Pharma Ip General Incorporated Association STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient
US9006252B2 (en) * 2008-09-26 2015-04-14 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
NZ591115A (en) 2008-09-26 2012-10-26 Boehringer Ingelheim Int Azaindazole compounds as ccr1 receptor antagonists
SI2396307T1 (sl) * 2009-02-11 2015-02-27 Merck Patent Gmbh Novi amino azaheterockliäśni karboksamidi
WO2012079079A1 (en) * 2010-12-10 2012-06-14 President And Fellows Of Harvard College Production of induced pluripotent stem cells
WO2014145512A2 (en) * 2013-03-15 2014-09-18 President And Fellows Of Harvard College Potent small molecule inhibitors of autophagy, and methods of use thereof
TW201920104A (zh) 2017-08-31 2019-06-01 美商馬愈法瑪公司 外核苷酸焦磷酸酶-磷酸二酯酶1(enpp-1)抑制劑及其用途

Similar Documents

Publication Publication Date Title
JP2021525752A5 (https=)
JOP20210001B1 (ar) مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
PH12020551205A1 (en) Fap inhibitors
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
EA202192910A1 (ru) Соединения, направленные на белки, и содержащие их фармацевтические композиции, и их терапевтическое применение
GEAP202215671A (en) Microbiocidal thiazole derivatives
BR112018072542A2 (pt) derivados de piridiniltriazol substituído com amida e usos dos mesmos
MX2025003876A (es) Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina
IL280358A (en) Novel autotac chimeric compound, and composition for preventing, ameliorating or treating diseases through targeted protein degradation comprosing the same
EA201791261A1 (ru) 1,3-тиазол-2-ил замещенные бензамиды
MX2019012445A (es) Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
EA202191991A1 (ru) Новые производные гетеротрициклического соединения и их применение
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
ME01456B (me) Fumaratna so (alfa s, beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoksi-alfa-1-naftalenil-beta-fenil-3-kinolinetanola
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
JOP20210127A1 (ar) مركبات عطرية غير متجانسة كمثبطات Vanin
JP2018186833A5 (https=)
JOP20210185A1 (ar) مركبات هالو-آلِّيلامين واستخدامها
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202192925A1 (ru) Твердые формы ингибитора glyt1
MX390418B (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso.
SG11202011427XA (en) Fish protein hydrolysate powder and a composition comprising said powder for use as a medicament
BR112021011368A2 (pt) Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos
HUE066894T2 (hu) Triszamid vegyületek és azokat tartalmazó készítmények